Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature
Authors
Keywords
-
Journal
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-07
DOI
10.1007/s11154-020-09618-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- (2020) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome
- (2019) Ana Luisa Perdigoto et al. Lancet Diabetes & Endocrinology
- Acquired Lipodystrophy Associated with Nivolumab in a Patient with Advanced Renal Cell Carcinoma
- (2019) Camila Kruschewsky Falcao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma
- (2019) C. Sakaguchi et al. Current Oncology
- T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors
- (2019) Sho Yoneda et al. DIABETES CARE
- Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes Mellitus With Infliximab
- (2019) Beckey Trinh et al. DIABETES CARE
- Immune checkpoint inhibitor‐induced Type 1 diabetes: a systematic review and meta‐analysis
- (2019) H. K. Akturk et al. DIABETIC MEDICINE
- Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
- (2019) Jeroen M.k. de Filette et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes
- (2019) Venessa H M Tsang et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pathogenesis of fulminant type 1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patient‐derived induced pluripotent stem cells for future research
- (2019) Yoshiya Hosokawa et al. Journal of Diabetes Investigation
- Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer
- (2019) Jin Sothornwit et al. Frontiers in Endocrinology
- The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors
- (2019) Lucien Marchand et al. ACTA DIABETOLOGICA
- Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes
- (2019) Alexandre Jehl et al. DIABETES CARE
- A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia
- (2019) Naoko Yamamoto et al. INTERNAL MEDICINE
- Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies
- (2019) Jingli Lu et al. Frontiers in Pharmacology
- Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC
- (2018) Nobuko Matsuura et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Programmed cell death-1 (PD-1) inhibitor induced type 1 diabetes mellitus: mini-review
- (2018) Katrien Clotman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report
- (2018) Won Jin Ho et al. Journal for ImmunoTherapy of Cancer
- Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype
- (2018) Lucien Marchand et al. ACTA DIABETOLOGICA
- Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
- (2018) Jordan J. Wright et al. DIABETES CARE
- Endocrine side effects of cancer immunotherapy
- (2017) Priscilla Cukier et al. ENDOCRINE-RELATED CANCER
- Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma
- (2017) Matthew A Smith-Cohn et al. Immunotherapy
- Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies
- (2017) Jean-Marie Michot et al. JOURNAL OF IMMUNOTHERAPY
- Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma
- (2017) Aikaterini Tsiogka et al. MELANOMA RESEARCH
- Immune‐Related Adverse Events as a Biomarker in Non‐Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
- (2017) Julia Judd et al. ONCOLOGIST
- The change of serum tumor necrosis factor alpha in patients with type 1 diabetes mellitus: A systematic review and meta-analysis
- (2017) Yong-chao Qiao et al. PLoS One
- Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes
- (2016) Sung Hye Kong et al. ACTA DIABETOLOGICA
- A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
- (2016) Elizabeth Hansen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
- (2016) Young Kwang Chae et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient
- (2016) Yukiko Teramoto et al. JOURNAL OF DERMATOLOGY
- Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes
- (2016) Yuka Miyoshi et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy
- (2016) Masahide Okamoto et al. Journal of Diabetes Investigation
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Abnormalities of the Exocrine Pancreas in Type 1 Diabetes
- (2015) Martha Campbell-Thompson et al. Current Diabetes Reports
- Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
- (2015) Mahnaz Mellati et al. DIABETES CARE
- Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
- (2015) Caroline Gaudy et al. DIABETES CARE
- Increased Immune Cell Infiltration of the Exocrine Pancreas: A Possible Contribution to the Pathogenesis of Type 1 Diabetes
- (2014) Teresa Rodriguez-Calvo et al. DIABETES
- Evolution of Abnormal Plasma Glucagon Responses to Mixed-Meal Feedings in Youth With Type 1 Diabetes During the First 2 Years After Diagnosis: Figure 1
- (2014) Jennifer Sherr et al. DIABETES CARE
- Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs -Cell Function
- (2012) S. A. Long et al. DIABETES
- Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
- (2012) C. J. Greenbaum et al. DIABETES
- Pancreas Organ Weight in Individuals With Disease-Associated Autoantibodies at Risk for Type 1 Diabetes
- (2012) Martha Campbell-Thompson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pancreatic Volume Is Reduced in Adult Patients with Recently Diagnosed Type 1 Diabetes
- (2012) Alistair J. K. Williams et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tumor Immunotherapy Directed at PD-1
- (2012) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Genetics of the HLA Region in the Prediction of Type 1 Diabetes
- (2011) Janelle A. Noble et al. Current Diabetes Reports
- Type 1 Diabetes and Interferon Therapy: A nationwide survey in Japan
- (2011) K. Nakamura et al. DIABETES CARE
- Etanercept Treatment in Children With New-Onset Type 1 Diabetes: Pilot randomized, placebo-controlled, double-blind study
- (2009) L. Mastrandrea et al. DIABETES CARE
- Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset
- (2009) Y. Kawabata et al. DIABETOLOGIA
- Amylase -2A Autoantibodies: Novel Marker of Autoimmune Pancreatitis and Fulminant Type 1 Diabetes
- (2008) T. Endo et al. DIABETES
- Fulminant type 1 diabetes in Caucasians: A report of three cases
- (2008) C. Moreau et al. DIABETES & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now